WO2008057580A3 - Materials and methods for treating and managing angiogenesis-mediated diseases - Google Patents

Materials and methods for treating and managing angiogenesis-mediated diseases Download PDF

Info

Publication number
WO2008057580A3
WO2008057580A3 PCT/US2007/023535 US2007023535W WO2008057580A3 WO 2008057580 A3 WO2008057580 A3 WO 2008057580A3 US 2007023535 W US2007023535 W US 2007023535W WO 2008057580 A3 WO2008057580 A3 WO 2008057580A3
Authority
WO
WIPO (PCT)
Prior art keywords
materials
treating
pathological angiogenesis
abnormal neovascularization
methods
Prior art date
Application number
PCT/US2007/023535
Other languages
French (fr)
Other versions
WO2008057580A2 (en
Inventor
Helen Marie Nugent
Elazer R Edelman
Tham Sjin Robert M Tjin
Yin Shan Ng
Original Assignee
Pervasis Therapeutics Inc
Helen Marie Nugent
Elazer R Edelman
Tham Sjin Robert M Tjin
Yin Shan Ng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pervasis Therapeutics Inc, Helen Marie Nugent, Elazer R Edelman, Tham Sjin Robert M Tjin, Yin Shan Ng filed Critical Pervasis Therapeutics Inc
Priority to CN2007800493079A priority Critical patent/CN101583367B/en
Priority to US12/513,564 priority patent/US20100092532A1/en
Priority to EP20070861841 priority patent/EP2079478A2/en
Priority to CA 2668621 priority patent/CA2668621A1/en
Priority to JP2009535364A priority patent/JP5372764B2/en
Priority to AU2007317789A priority patent/AU2007317789B2/en
Publication of WO2008057580A2 publication Critical patent/WO2008057580A2/en
Publication of WO2008057580A3 publication Critical patent/WO2008057580A3/en
Priority to IL198535A priority patent/IL198535A0/en
Priority to AU2011202132A priority patent/AU2011202132B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Disclosed herein are materials and methods suitable for treating sites of pathological angiogenesis and abnormal neovascularization. Sites of pathological angiogenesis or abnormal neovascularization can be treated by contacting a surface at or adjacent or in the vicinity of an area of pathological angiogenesis or abnormal neovascularization with an implantable material. The implantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the affected site. The composition can be a flexible planar material or a flowable composition. Diseases susceptible to treatment with the present invention include, for example, macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic inflammatory diseases, and treatment of tumors by surgical resection, radiation therapy or chemotherapy.
PCT/US2007/023535 2006-11-07 2007-11-07 Materials and methods for treating and managing angiogenesis-mediated diseases WO2008057580A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN2007800493079A CN101583367B (en) 2006-11-07 2007-11-07 Materials and methods for treating and managing angiogenesis-mediated diseases
US12/513,564 US20100092532A1 (en) 2006-11-07 2007-11-07 Materials and Methods for Treating and Managing Angiogenesis-Mediated Diseases
EP20070861841 EP2079478A2 (en) 2006-11-07 2007-11-07 Materials and methods for treating and managing angiogenesis-mediated diseases
CA 2668621 CA2668621A1 (en) 2006-11-07 2007-11-07 Materials and methods for treating and managing angiogenesis-mediated diseases
JP2009535364A JP5372764B2 (en) 2006-11-07 2007-11-07 Materials and methods for the treatment and management of angiogenesis-related diseases
AU2007317789A AU2007317789B2 (en) 2006-11-07 2007-11-07 Materials and methods for treating and managing angiogenesis-mediated diseases
IL198535A IL198535A0 (en) 2006-11-07 2009-05-04 Materials and methods for treating and managing angiogenesis-mediated diseases
AU2011202132A AU2011202132B2 (en) 2006-11-07 2011-05-09 Materials and methods for treating and managing angiogenesis-mediated diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US85745806P 2006-11-07 2006-11-07
US60/857,458 2006-11-07
US87562606P 2006-12-19 2006-12-19
US60/875,626 2006-12-19
US92383607P 2007-04-17 2007-04-17
US60/923,836 2007-04-17
US96702907P 2007-08-30 2007-08-30
US60/967,029 2007-08-30

Publications (2)

Publication Number Publication Date
WO2008057580A2 WO2008057580A2 (en) 2008-05-15
WO2008057580A3 true WO2008057580A3 (en) 2008-07-31

Family

ID=39365137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023535 WO2008057580A2 (en) 2006-11-07 2007-11-07 Materials and methods for treating and managing angiogenesis-mediated diseases

Country Status (9)

Country Link
US (1) US20100092532A1 (en)
EP (1) EP2079478A2 (en)
JP (2) JP5372764B2 (en)
CN (2) CN101583367B (en)
AU (2) AU2007317789B2 (en)
CA (1) CA2668621A1 (en)
IL (1) IL198535A0 (en)
SG (1) SG176460A1 (en)
WO (1) WO2008057580A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5372764B2 (en) * 2006-11-07 2013-12-18 シャイア リジェネラティブ メディシン， インコーポレイテッド Materials and methods for the treatment and management of angiogenesis-related diseases
US20100239671A1 (en) * 2007-11-06 2010-09-23 Edelman Elazer R Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair
US9629798B2 (en) 2008-04-03 2017-04-25 Mallinckrodt Pharma Ip Trading D.A.C. Hemostatic microspheres
CA2751460A1 (en) * 2009-02-04 2010-08-12 Massachusetts Institute Of Technology Compositions and uses to govern cancer cell growth
CN109134604B (en) * 2017-06-16 2022-04-22 首都医科大学 1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-GRGDF, and synthesis, activity and application thereof
CN111518746A (en) * 2020-05-18 2020-08-11 南通大学 Preparation method and application of pellet in corneal micro-pocket surgery experiment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062871A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Materials and methods for minimally-invasive administration of a cell-containing flowable composition
WO2006062909A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
WO2006062962A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Materials and methods for treating and managing plaque disease
WO2006116357A1 (en) * 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
WO2007001744A2 (en) * 2005-06-21 2007-01-04 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
WO2007047425A1 (en) * 2005-10-12 2007-04-26 Cellular Bioengineering, Inc. Resorbable cornea button

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418691A (en) * 1981-10-26 1983-12-06 Massachusetts Institute Of Technology Method of promoting the regeneration of tissue at a wound
US4787900A (en) * 1982-04-19 1988-11-29 Massachusetts Institute Of Technology Process for forming multilayer bioreplaceable blood vessel prosthesis
US4820626A (en) * 1985-06-06 1989-04-11 Thomas Jefferson University Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US6309635B1 (en) * 1986-11-20 2001-10-30 Children's Medical Center Corp. Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo
US5736372A (en) * 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5567612A (en) * 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
US5759830A (en) * 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
CA1340581C (en) * 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
CH676195A5 (en) * 1988-10-07 1990-12-28 Sulzer Ag
AU6747790A (en) * 1989-11-13 1991-06-13 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5527532A (en) * 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5540928A (en) * 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
JPH05247097A (en) * 1992-02-14 1993-09-24 Makoto Goto Blood vessel growth-depressing factor
US5399665A (en) * 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US6491938B2 (en) * 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US6176874B1 (en) * 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
ATE198979T1 (en) * 1994-10-12 2001-02-15 Focal Inc TARGETED DISHES ADMINISTERED USING BIODEGRADABLE POLYMERS
US6911216B1 (en) * 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US5914268A (en) * 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5766584A (en) * 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
US6615071B1 (en) * 1995-09-20 2003-09-02 Board Of Regents, The University Of Texas System Method and apparatus for detecting vulnerable atherosclerotic plaque
US6886568B2 (en) * 1998-04-08 2005-05-03 The Johns Hopkins University Method for fabricating cell-containing implants
AU766693B2 (en) * 1998-11-24 2003-10-23 Emory University Transgenic circulating endothelial cells
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US6387116B1 (en) * 1999-06-30 2002-05-14 Pharmasonics, Inc. Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
JP2003519473A (en) * 1999-11-24 2003-06-24 アーネスト ジー． ホープ Anti-angiogenic cellular substances for cancer treatment
DE60130544T2 (en) * 2000-03-13 2008-06-26 Biocure, Inc. EMBOLIC COMPOSITIONS
CA2400319C (en) * 2000-03-15 2008-09-16 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US6506398B1 (en) * 2000-04-28 2003-01-14 Hosheng Tu Device for treating diabetes and methods thereof
AU2001296558A1 (en) * 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6565601B2 (en) * 2000-11-15 2003-05-20 Micro Therapeutics, Inc. Methods for vascular reconstruction of diseased arteries
JP2002201138A (en) * 2000-12-28 2002-07-16 Japan Tissue Engineering:Kk Neovascularization inhibitor
NZ527046A (en) * 2001-01-16 2005-06-24 Vascular Therapies Llc A flexible cylindrical matrix material, preferably collagen with an antiproliferative agent preferably rapamycin dispersed throughout for implantation to be in contact with a vascular structure
US6723131B2 (en) * 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit
KR20050044393A (en) * 2001-11-09 2005-05-12 아르테셀 사이언스, 인크. Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
US20040047843A1 (en) * 2002-02-12 2004-03-11 Uab Research Foundation Method for spinal cord reconnection
US20050008629A1 (en) * 2002-05-08 2005-01-13 Interpore Orthopaedics, A Delaware Corporation Encapsulated AGF cells
DK1542536T3 (en) * 2002-07-25 2012-01-23 Scripps Research Inst Hematopoietic stem cells and methods for treating neovascular eye diseases therewith
US20050106554A1 (en) * 2003-11-19 2005-05-19 Palecek Sean P. Cryopreservation of pluripotent stem cells
PL1951344T3 (en) * 2005-11-07 2015-02-27 Borla Ind Vented safe handling vial adapter
JP5372764B2 (en) * 2006-11-07 2013-12-18 シャイア リジェネラティブ メディシン， インコーポレイテッド Materials and methods for the treatment and management of angiogenesis-related diseases
US8579814B2 (en) * 2007-01-05 2013-11-12 Idexx Laboratories, Inc. Method and system for representation of current and historical medical data

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062871A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Materials and methods for minimally-invasive administration of a cell-containing flowable composition
WO2006062909A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
WO2006062962A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Materials and methods for treating and managing plaque disease
WO2006116357A1 (en) * 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
WO2007001744A2 (en) * 2005-06-21 2007-01-04 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
WO2007047425A1 (en) * 2005-10-12 2007-04-26 Cellular Bioengineering, Inc. Resorbable cornea button

Also Published As

Publication number Publication date
WO2008057580A2 (en) 2008-05-15
IL198535A0 (en) 2010-02-17
AU2011202132B2 (en) 2012-09-20
AU2007317789B2 (en) 2011-02-10
US20100092532A1 (en) 2010-04-15
CN101583367A (en) 2009-11-18
JP2013048953A (en) 2013-03-14
SG176460A1 (en) 2011-12-29
CN103230414A (en) 2013-08-07
AU2007317789A1 (en) 2008-05-15
CA2668621A1 (en) 2008-05-15
JP5372764B2 (en) 2013-12-18
AU2011202132A1 (en) 2011-05-26
EP2079478A2 (en) 2009-07-22
CN101583367B (en) 2013-05-01
JP2010509228A (en) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2008057580A3 (en) Materials and methods for treating and managing angiogenesis-mediated diseases
WO2010017451A3 (en) Medical device for bone implant and method for producing such a device
WO2006109044A3 (en) Selective modulation of tumour necrosis factor receptors in therapy
WO2009126571A3 (en) Nanoparticle-mediated microwave treatment methods
WO2007143231A3 (en) Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
WO2005072764A3 (en) Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
WO2009020650A3 (en) Materials and methods for treating and managing wounds and the effects of trauma
WO2010002799A3 (en) Isolated extracellular matrix material including subserous fascia
WO2011143572A8 (en) Implantable mechanical support
WO2007004060A3 (en) Cytokine receptor modulators and uses thereof
UA86400C2 (en) Normal;heading 1;heading 2;USE OF LOW-DOSE ERYTHROPOIETIN FOR PATIENTS WITH DYSFUNCTION OF ENDOTHELIAL PRECURSOR CELLS, CARDIOVASCULAR RISK FACTOR AND END ORGAN DAMAGES
TW200722090A (en) Compounds useful for inhibiting chk1
EP3818991A3 (en) Compositions and methods for treating diseases
Cavalu et al. BIOACTIVITY AND ANTIMICROBIAL PROPERTIES OF PMMA/Ag 2 O ACRYLIC BONE CEMENT COLLAGEN COATED.
ATE553771T1 (en) RTEF-1 VARIANTS AND THEIR USE TO INHIBIT ANGIOGENESIS
WO2007100728A3 (en) Mannose derivatives for killing tumor cells
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
ATE549017T1 (en) USE OF TRANILAST AND ITS DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS
WO2006044486A3 (en) Methods and compositions for the utilization and targeting of osteomimicry
MA32384B1 (en) Pharmaceutical compositions
Xu et al. Transfection of human tumour cells with Mre11 siRNA and the increase in radiation sensitivity and the reduction in heat-induced radiosensitization
PT1107795E (en) TIOMOLIBDATE ASSOCIATED WITH AT LEAST A CARBON HYDRATE AND ITS USE TO AVOID OR TREAT DISEASES CHARACTERIZED BY A VASCULARIZATION SUCH AS MACULAR DEGENERATION CANCER OF THE HUMID TYPE RHEUMATOID ARTHRITIS
BRPI0410875A (en) Tumor Factor Growth Inhibition Method
BR0316290A (en) Method of Treating Interstitial Cystitis
US20110141649A1 (en) Method for producing insulated electrodes for applying electric fields into conductive material

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780049307.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007317789

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009535364

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 198535

Country of ref document: IL

REEP Request for entry into the european phase

Ref document number: 2007861841

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2668621

Country of ref document: CA

Ref document number: 2007861841

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1789/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007317789

Country of ref document: AU

Date of ref document: 20071107

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12513564

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861841

Country of ref document: EP

Kind code of ref document: A2